Retrophin, Inc. has sold its priority review voucher to Sanofi for $245 million in cash. In March, Retrophin bought small drugmaker, Asklepion Pharmaceuticals, for roughly $75 million, gaining Cholbam (cholic acid), a drug approved by the US Food and Drug Administration (FDA). Retrophin has already gained that $75 million back …